6533b835fe1ef96bd12a010e
RESEARCH PRODUCT
Management of Intra-abdominal Infections due to Carbapenemase-Producing Organisms.
Vitale FrancescoCriostóir Ó’SúilleabháinCasuccio AlessandraPaola Di Carlosubject
medicine.medical_specialtySettore MED/17 - Malattie InfettiveIaisIntra-abdominal infections . Carbapenemase-producing organisms . Carbapenem-resistant Enterobacteriaceae . Management of intra-abdominal infectionsAbdominal InfectionCarbapenem-resistant enterobacteriaceaeBiologySettore MED/42 - Igiene Generale E ApplicataAntimicrobialbiology.organism_classificationMicrobiologySettore MED/18 - Chirurgia GeneraleInfectious DiseasesMedical microbiologyAntibiotic resistanceInfectious disease (medical specialty)medicineInfection controlIntensive care medicinedescription
The prevalence of bacterial resistance to carbapenem antibiotics continues to increase because of bacteria producing metallo-β-lactamases (MBL), called carbapenemase-producing organisms (CPO). Enterobacteriaceae, which can be a common cause of intra-abdominal infections (IAIs), have become carbapenem-resistant Enterobacteriaceae (CRE). Updated international guidelines for the treatment of both IAIs and IAIs due to CRE have been published. Given the multifaceted nature of these infections, these recommendations have been jointly reviewed and endorsed by the Surgical Society and the Association of Medical Microbiology and Infectious Disease. The aims of this review are to summarize the general and new generation of multimodal procedure to manage IAIs due to CRE and review the data available on the combination of interventions to reduce CRE. Future research should focus on the development of novel and safe antimicrobial therapies and the quantification of the incremental effect of infection control programmes and new methods to rapidly detect pathogens before patients enter the surgical setting.
year | journal | country | edition | language |
---|---|---|---|---|
2014-08-18 | Current infectious disease reports |